New psoriasis drug matches up against stelara in head-to-head trial
NCT ID NCT05335356
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 32 times
Summary
This study tested whether a new drug called Bmab 1200 works as well as the approved drug Stelara for people with moderate to severe plaque psoriasis. 384 adults took part and received either Bmab 1200 or Stelara. The main goal was to see how much their psoriasis improved after 12 weeks using a standard skin score. This is a disease-control study, meaning the treatment aims to manage symptoms long-term, not cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Clinical Research Center
Mayfield Heights, Ohio, 44124, United States
Conditions
Explore the condition pages connected to this study.